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Abstract A poorly understood feature of the tauopathies is
their very different clinical presentations. The frontotemporal
lobar degeneration (FTLD) spectrum is dominated by motor
and emotional/psychiatric abnormalities, whereas cognitive
and memory deficits are prominent in the early stages of
Alzheimer’s disease (AD).We report two novelmousemodels
overexpressingdifferent human tauprotein constructs.One is a
full-length tau carrying a doublemutation [P301S/G335D; line
66 (L66)] and the second is a truncated 3-repeat tau fragment
which constitutes the bulk of the PHF core in AD
corresponding to residues 296–390 fused with a signal
sequence targeting it to the endoplasmic reticulum membrane
(line 1;L1). L66has abundant tau pathologywidely distributed
throughout the brain, with particularly high counts of affected
neurons in hippocampus and entorhinal cortex. The pathology
is neuroanatomically static and declines with age. Behavio-
urally, themodel is devoid of a higher cognitive phenotype but
presents with sensorimotor impairments and motor learning
phenotypes. L1 displays a much weaker histopathological
phenotype, but shows evidence of neuroanatomical spread and
amplificationwith age that resembles theBraak staging ofAD.
Behaviourally, the model has minimal motor deficits but
shows severe cognitive impairments affecting particularly the
rodent equivalent of episodic memory which progresses with
advancing age. In both models, tau aggregation can be disso-
ciated from abnormal phosphorylation. The two models make
possible the demonstration of two distinct but nevertheless
convergent pathways of tau molecular pathogenesis. L1
appears to be useful formodelling the cognitive impairment of
AD, whereas L66 appears to be more useful for modelling the
motor features of the FTLD spectrum. Differences in clinical
presentation of AD-like and FTLD syndromes are therefore
likely to be inherent to the respective underlying tauopathy,
and are not dependent on presence or absence of concomitant
APP pathology.
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Introduction
Neurodegeneration associated with abnormal processing of
tau protein is increasingly recognised as having an
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important role in a number of societally important neuro-
degenerative disorders. Alzheimer’s disease was the first
and most prevalent to be recognised as implicating the
pathological aggregation of tau protein [1]. It is charac-
terised histologically by the formation of intracellular
neurofibrillary tangles (NFTs) first described by Alzheimer
[2]. At the ultrastructural level the tangle is a dense array of
Paired Helical Filaments (PHFs; [3]). These are de novo
pathological polymers of which the principal constituent is
a truncated, 100-amino acid fragment of the microtubule-
associated protein tau [1, 4, 5]. This truncated fragment can
catalyse the conversion of normal soluble tau into aggre-
gated forms [6] which, in turn, can spread to neighbouring
neurons [7–12]. The pattern of spread of tau-aggregation
pathology in the human brain is highly stereotyped, and
forms the basis of the six-step Braak staging system for
neurofibrillary degeneration in AD [13]. A correlation
between Braak stage and cognitive decline has been con-
firmed in numerous studies [14–18] with clinical dementia
appearing at about stage 4 [18]. Stage 1 pathology appears
already by the 4th–5th decade of life, preceding by some
27 years the appearance of amyloid b pathology [16, 19].
A poorly understood feature of tau-linked neurodegen-
eration is the very different clinical presentations of the
associated syndromes. Whether or not linked to mutations
in the MAPT gene, the clinical features of the frontotem-
poral lobar degeneration (FTLD) spectrum are generally
dominated by motor and emotional/psychiatric abnormal-
ities, whilst cognitive deficits tend to be rarer, more subtle
and present at later disease stages [20]. In AD, on the other
hand, the clinical features are dominated by cognitive and
memory deficits occurring early in the disease, in the
almost complete absence of motor abnormalities until very
advanced disease stages. One possible explanation is that
the difference depends on the presence of concomitant
pathology linked to the amyloid b protein pathway. Indeed,
animal studies of combined amyloid precursor protein
(APP)/tau models have tended to emphasise tau as merely
an aggravating or accelerating factor in what is concep-
tualised primarily as a disorder of APP processing [21].
However, given that 19 trials at phase 2 or 3 with drugs
targeting various aspects of this pathway have so far failed
to deliver convincing cognitive benefit [22] and that amy-
loid load is poorly correlated with cognitive impairment, it
is not clear that an abnormality in APP processing con-
tributes to cognitive impairment in AD. An alternative
possibility is that the dissociation between motor and
cognitive abnormalities seen in the various clinical tauop-
athies is actually inherent to differences in the underlying
molecular pathophysiology of tau protein itself.
Familial autosomal dominantly inherited MAPT muta-
tions have formed the basis of the majority of tau transgenic
mouse models developed to date. The majority of these
models express cDNA mutated in exon 10 (P301L, P301S,
N279K), exon 9 (G272V), exon 13 (R406W) or exon 12
(V337M) and these present with intracellular aggregates of
tau in neurons and glial cells (for review, see [23]). Motor
phenotypes are common to most mutations in exon 10, while
there is some suggestion that cognitive and emotional
abnormalities may have a greater association with exons 9,
12 and 13 mutations [24]. We here report a novel FTDP-17
mouse model, in which the longest human MAPT cDNA in
the central nervous system (htau40; 441 amino acids),
containing 4 repeats and including point mutations P301S
and G335D [termed Line 66 (L66)], was expressed under
the Thy-1 regulatory element. Clinically, the P301S muta-
tion causes early onset and rapid progression of disease
associated with lowered microtubule assembly in patients
and in mouse models with different tau isoforms (4R/0N
[25] 4R/1N [26] 4R/2N [27]). The resulting L66 mice are
characterised by severe neurofibrillary pathology associated
with a prominent motor phenotype occurring in the absence
of any higher cognitive features despite abundant tangles
being present in hippocampus and entorhinal cortex. L66
mice also exhibit neuropathological features characteristic of
a degenerative axonopathy.
Given the limitations of transgenic models based on
MAPT mutations as models for AD, we have developed an
alternative approach based on the truncated tau fragment
restricted to the repeat domain which is the principal
constituent of PHFs [28]. Cleavages at Glu-391 and/or
Asp-421 result in tau fragments which appear relatively
early in the disease state and induce toxicity in transfected
cells in vitro [29, 30]. Rats transgenic for a truncated
human tau fragment encompassing residues tau151–391
present with symptoms of neurodegeneration, intracellular
accumulation of human tau in neurons [31], reduced life
span [32], and late onset sensorimotor impairment
([9 months) [33]. We report here the development of a
new tau transgenic line (Line 1, L1) in which mice express
truncated tau296–390 similar to fragment of tau isolated
from AD PHFs [1] and that is targeted to the endoplasmic
reticulum (ER) membrane. We report here that L1 mani-
fests a strong cognitive phenotype occurring in the absence
of prominent sensorimotor features. The tau pathology seen
in L1 remains at the stage of diffuse oligomeric aggregates,
and does not progress histologically to tangles.
Materials and methods
Cloning of the constructs and generation of transgenic
mice
L1 and L66 transgenic mice were generated using two
different constructs. (a) Plasmid pSS296–390, which
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contains the human tau cDNA, encoding amino acids
296–390 of the longest human tau isoform (htau40) [34]
was used to generate L1 mice. The plasmid contained an
N-terminal signal sequence for insertion of the nascent
polypeptide into the membrane of the ER, as well as 50- and
30-untranslated sequences targeting the mRNA to mem-
brane-bound ribosomes and supporting insertion of the
signal sequence into the ER membrane [35]. Neuronal
expression was ensured through insertion of the construct
into the murine Thy-1 expression cassette (pTSC21k)
kindly provided by H. van der Putten, Basel [36].
(b) Plasmid pP301S/G335D containing the longest human
isoform (htau40, 441amino acids) in which two point
mutations at positions ?900 (C ? T) and ?1,003
(G ? A) were introduced by PCR-directed mutagenesis.
These mutations alter the codons for the amino acid
changes P301S and G335D, respectively. The cDNA was
inserted into the Thy-1 cassette to generate L66 mice.
The vectors were cloned, sequences confirmed and a
linearized NotI DNA fragment was microinjected into
fertilized NMRI mouse eggs according to standard tech-
niques [37]. Founder mice were identified by PCR using
appropriate Thy-1 (50-gcaggaggtgctcagggacagc-30; 50-tacca
gctggctgacctgtagc-30) and Tau primers (50-gagctccct
catccactaag-30) resulting in 230 and 970 bp fragments for
the L1 and L66 constructs, respectively. Genomic DNA
was prepared using DNeasyTM tissue kit (Qiagen) and the
number of integrations and copy number of transgenes
were determined by Southern blot.
Determination of copy numbers in different transgenic
founders by Southern blot
DNA was prepared from tail biopsies, digested with EcoRI
and separated electrophoretically on agarose gels.
Restriction fragments were transferred onto a nylon
membrane by capillary blotting and hybridised to NcoI/
XbaI fragments of the Thy-1 promoter cassette. Wild-type
alleles are recognised by an 8,200 bp EcoRI restriction
fragment corresponding to two copies and transgenic allele
is recognised by a approximately 5,000 bp EcoRI restric-
tion fragment. Quantitative analysis was performed with
ImageQuant software (Molecular Dynamics) with aver-
age intensity of all pixels in retrieved spots taken as
measure.
Animals
Founders were expanded with NMRI (Charles River,
Germany) wild types before interbreeding heterozygous
offspring for several generations to attain homozygous
lines. Unless otherwise stated, all experiments were con-
ducted using homozygous L1 and L66 mice with a
preference for female gender in the behavioural charac-
terisation. Mice were typically housed singly or in small
colonies (up to 10) in Type 2 Macrolon or shoebox cages
with free access to water and food in climatized holding
rooms under a 12 h day night cycle (lights on at 7.00 a.m.).
Experiments were carried out in accordance with the
European Communities Council Directive (63/2010/EU), a
project licence with local ethical approval under the UK
Animals (Scientific Procedures) Act (1986) or in accor-
dance with the German Law for Animal Protection
(Tierschutzgesetz).
Immunoblotting
Mouse brains were harvested from 4-month-old wild-type
or L1, and 10- to 12-month-old wild-type or L66 animals.
Brain (approximately 0.5 g) was homogenised in 1.5 ml
sodium-phosphate (5 mM), sucrose (0.32 M, pH 7.0),
MgCl2 (1 mM) and EGTA (1 mM) with protease inhibi-
tors (Roche Complete PIC). Homogenates were diluted
fivefold into gel sample buffer and samples (10 ll) sep-
arated by electrophoresis using 15 % SDS-PAGE gels.
Truncated tau (297–391; dGAE; [4]) (50 ng) and full-
length tau (T40; 250 ng) were included as positive anti-
body controls. Proteins were separated on gels using a
Laemmli buffer system and blotted, using Tris
(12.5 mM), glycine (96 mM) buffer (pH 8.8), onto PVDF
membrane in a BioRad Mini Protean II gel electrophoresis
tank. Blocking in buffer (5 % Marvel milk powder in
PBS) lasted 30 min followed by incubation with primary
antibodies and HRP-labelled secondary antibodies diluted
in blocking buffer for 1 h and three 10-min washes
between each antibody. Bound antibody was detected by
enhanced chemiluminescence using Immun-Star HRP
substrate (Bio-Rad) and a Carestream 2200PRO Imager.
The following primary tau antibodies were used. (1)
Monoclonal antibody (mAb) 7/51 recognises a tau epitope
generic for all 6 tau CNS isoforms and an epitope that is
located in the third tau repeat [38]. The epitope is
occluded when tau is bound in a paired helical filament
(PHF)-like immunochemical configuration but can be
exposed by formic acid pre-treatment [39]. (2) N-terminal
specific mAb 27/342 recognises a generic tau epitope
between Ser-208 and Ser-238 [6]. (3) mAb 27/499 rec-
ognises a human-specific epitope between Gly-16 and
Gln-26 [6]. (4) K9JA, a rabbit polyclonal antiserum raised
against the C-terminal 243–441 residues of tau (Dako,
A0024). (5) T46, a mAb specific to the C-terminal amino
acids 404–441 of human tau (Invitrogen, 13-6400). All of
these tau antibodies are phospho-independent. Secondary
horseradish peroxidase conjugated antibodies were from
Sigma (anti-rabbit) and Bio-Rad (anti-mouse). Primary
antibodies were used as 1:10 dilutions of hybridoma
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supernatants (mAbs 7/51, 423 and 27/499), 1:1,000 for
purified K9JA and T46 and 1:1,000 for secondary
antibodies.
Bielschowsky silver staining
Dewaxed sections were stained for 20 min at room tem-
perature in darkness using 10 % silver nitrate or until
coloured light brown, and washed three times with distilled
water. They were then incubated in ammoniacal silver
nitrate solution (20 %) for 20 min at room temperature,
again washed three times, developed in ammoniacal silver
nitrate including five drops of developer (20 ml of 37 %
formaldehyde, 0.5 g citrate, 1 drop 65 % nitric acid,
100 ml distilled water) until gold-brown, washed again and
dehydrated before mounting in Entellan (Merck).
Primulin staining
The thioflavin S staining protocol described by Sun and co-
workers [40] was adapted for use with primulin [41]. In
brief, sections were dewaxed, rehydrated by passage
through graded alcohols, antiquenched with 0.25 %
KMnO4 and 1 % sodium borohydride and stained with
0.05 % primulin in 50 % ethanol. Photobleaching was
blocked by concentrated phosphate buffer and sections
were mounted with Vectashield.
Quantification of tau-immunoreactive cells
Whole brains were removed from the skulls, fixed in 4 %
paraformaldehyde in PBS (pH 7.4), and then wax embedded,
sectioned, prepared and stained as described previously [42].
For explorative pathology, sections were taken from
numerous parts of brain along the fronto-caudal axis. Par-
ticular interest centred on cortical structures and these were
identified in repeat sections according to the stereotactic
mouse atlas [43]; they included entorhinal cortex (ERC),
hippocampus (Hip; polymorphic cells of dentate gyrus, CA3
and CA1), retrosplenial cortex (RSC), visual cortex (VC),
auditory cortex (AC), subiculum (S), amygdala (A).
The primary antibody used for quantification was mAb
7/51 (1:350 dilution). Bound primary antibody was
amplified using the Vectastain ABC Kit (Vector Labo-
ratories) as per manufacturer and visualised using
diaminobenzidine (DAB). Sections were counterstained
with haematoxylin (Dr. K. Hollborn & Sons).
Histological analysis of L66 mouse brains
For visualisation of disintegrative degeneration and quali-
tative assessment of tau pathology in brain of L66, mice
were killed under terminal anaesthesia and then perfused
with type 3 perfusion fix (EM Sciences), brain kept in
skulls for 12–16 h in fixative before transferring to PBS
storage buffer. Brains were embedded in MultiBrain
blocks and free-floating cryosections (30 lm) made of the
entire block. A set of every eighth section was stained by
the same procedure, selected from: (a) amino cupric silver
stain according to de Olmos et al. [44]; (b) immunostaining
with biotinylated mAb AT8 (ThermoScientific; 100 lg/ml
used at 1:5,000); (c) immunostained with antibody for glial
fibrillary acidic protein (GFAP) (Dako; 1:20,000) followed
by goat anti-rabbit Vecta Elite (Vector Laboratories) and
(d) immunostained with mAb 7/51 (1:500) followed by
horse anti-mouse Vecta Elite.
Qualitative staining with mAbs 7/51 and AT8
(pSer202/Thr205; [45]) was performed using EnVision
double staining system (Dako). Polyclonal p-Tau (S-404)
antibody (Santa Cruz) was used on sections at a dilution
of 1:1,000.
Electron microscopy
Spinal cord tissue from 8- to 9-month-old L66 mice (4
wild-type and 4 L66 mice in equal numbers of male and
female genders) was removed from animals perfused
through the abdominal aorta with 0.05 % glutaraldehyde
and 3 % para-formaldehyde in 0.1 M sodium cacodylate
buffer (pH 7.35) containing 4 % hydroxyethyl starch.
Spinal cords were taken and immersed in the same fixa-
tive for 24 h at 4 C, and cryoprotected in 2.3 M sucrose
at 4 C overnight. The tissue was then frozen in liquid
nitrogen, and blocks of 1.0 mm3 sectioned at -80 C.
Ultrathin sections (70 nm) were retrieved at -100 C in
2.3 M sucrose with 2 % methyl cellulose, and transferred
to formvar/carbon-coated nickel grids. Immunolabeling
entailed rinse of specimen in 0.1 M PBS followed by
blocking for 30 min using 5 % goat serum (Sigma G9023)
in 0.1 M PBS. Rabbit anti-tau (Sigma T6402; diluted
1:1,000 in 5 % goat serum/PBS) was applied at 4 C
overnight, washed repeatedly with goat serum/PBS and
incubated with 10-nm gold-conjugated secondary anti-
body (Amersham RPN 421; diluted 1:40 in 5 % goat
serum/PBS) at room temperature for 60 min. After
washing with 0.1 M PBS, sections were fixed with glu-
taraldehyde (2.5 % in 0.06 M PBS) at room temperature
for 5 min, rinsed with water, floated on a droplet of uranyl
acetate (4 % in water) at 4 C for 4 min and transferred to
a droplet of 0.4 % uranyl acetate/2 % methyl cellulose.
Labelled grids were dried for C30 min at room temper-
ature and examined in a Zeiss EM906 electron
microscope at 80 kV. The investigator was blinded with
respect to the genotype.
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Behavioural phenotyping
Sensorimotor screen
A number of tests were conducted to determine sensory
motor abilities, global gait function and motor learning in
both L1 and L66 lines.
Catwalk: Gait analysis was performed on freely walking
mice using the CatWalk (Noldus, Wageningen, The
Netherlands). Three trials per mouse were administered
enabling the mouse to traverse the glass plate from East to
West (and vice versa) at a maximum of 5 s. Data were
recorded automatically (Catwalk software version 7)
including relative paw position (hind overlapping/non-
overlapping with front paws), timing (stand, swing and step
cycle), base of support, pressure and dimensions of each
footfall, which enabled calculation of stride length and paw
distance, regularity index (preferred paw placement
sequence during walking). As for all behavioural tests,
apparatus was wiped with 70 % ethanol between animals.
Balance beam: Sensorimotor coordination was tested
using one set of square and one set of round balance beams
(50-cm length; 28-, 12- or 5-mm in cross-section; 30
incline). Subjects were given one trial per beam (from big
to small) and latency to traverse the beam was scored and
averaged. Failure to traverse the beam during the allotted
time terminated the trial and the maximum time (30 s) was
recorded. Beams were wiped with 70 % ethanol between
animals.
RotaRod: An automated 4-lane accelerating RotaRod
(TSE, Germany) was used to examine motor coordination
and motor learning. Testing consisted of four trials per day
for 3 consecutive days with inter-trial intervals of 2–3 min.
Mice were placed on a slowly rotating rod [1 rotation per
minute (rpm)] and the rod was accelerated from 1 to
45 rpm over the trial time of 5 min. Trials were terminated
when animals fell off the rod or the maximum time was
achieved. Lanes were allocated following a Latin square
design to counterbalance for both rod position and time of
testing. The apparatus was cleaned with 70 % ethanol
between trials.
Cognitive testing in open field water maze
The water maze was a cylindrical, grey Perspex pool (150-
cm diameter; 50-cm height). It was filled with water
(21 ± 1 C) and a clear Perspex, circular, rigid escape
platform (10-cm diameter, 35-cm height) was submerged
about 1 cm below the water surface. It was placed in a
laboratory with plenty extra-maze cues. The mice were
released into the pool facing the wall at one of four cardinal
points: North, East, South and West. Swim paths were
registered with an overhead CCTV camera and online
processed using the image analyser Ethovision 3.1Pro
(Noldus IT, Wageningen, The Netherlands). All recordings
were also stored on video tape or DVD.
Reference memory: The reference memory acquisition
training was conducted over 4 days with six trials per day,
and an inter-trial interval (ITI) of 10 min (Days 1–4). The
platform was positioned within the centre of one quadrant
of the pool and remained at the fixed location throughout.
All four platform locations were used and counter balanced
with genotype. A maximum trial length of 60 s was
allowed with 30 s on the platform. Animals not finding the
platform location during this time were gently guided to it.
Data extracted from the recording included overall path
length as spatial learning index, swim speed as a proxy for
motor ability, and wall hugging (thigmotaxis) as an escape
strategy implemented early in the learning phase and pro-
gressively diminishing.
One hour after the last day of acquisition training, a
probe test was conducted. The platform was removed from
the pool and mice were released facing the wall, directly
opposite the training quadrant and were allowed to swim
freely for 60 s. Time spent in each quadrant was used as an
index of spatial bias.
Problem solving: The protocol was adapted from Chen
and co-workers [46] and included a cued training phase
followed by the training to criterion test involving a series
of spatial learning tasks (‘‘problems’’) with a hidden plat-
form. Cued training: the pool was surrounded by white
curtains to occlude sight of extra-maze cues. The platform
was cued by a flag placed onto it (approximately 15-cm
high) and the platform location was changed for each trial
in a predetermined fashion to one of 20 possible sites.
Animals were trained for 4 consecutive days and received 4
trials per day. Training to criterion: the curtains were
withdrawn to reveal extra maze cues and the platform
submerged about 1 cm below the water surface. Each
animal was trained for up to eight trials per day for a
maximum of 2 weeks to a rigorous performance criterion
of three successive trials with an escape latency of less than
20 s. If the criterion was achieved before the eight daily
trials were given, then the session for this animal was
terminated and a new problem (new platform location) was
implemented on the following day. The number of trials
required to reach criterion for each problem was calculated
as the primary measure of the animal’s learning capacity.
Anxiety test: light/dark box
Line 1 mice (7–8 months) were tested in the light/dark box.
The apparatus consisted of two Perspex boxes: an open
white compartment (30 cm length 9 30 cm wide 9 30 cm
height) brightly illuminated and a smaller dark compart-
ment (30 cm length 9 20 cm wide 9 25 cm height)
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covered with a dark Perspex lid. The compartments were
connected by an aperture at floor level. Animals were
individually placed into the brightly lit compartment facing
the opening and allowed to freely explore the apparatus for
10 min. Time spent and numbers of entries into each
compartment were extracted from video-tracked recordings
(Ethovision XT6) as indicators of anxiety.
Data analysis
Results are presented as mean ± SE and were analysed
using parametric statistics. Typically, comparisons applied
factorial analysis of variance (ANOVA) with genotype as
between-subject and trial/day/age/region as within-subject
factor followed by Bonferroni corrected t tests, or used
simple 1-way ANOVA followed post hoc by Student’s
t test. Contrast with chance was confirmed by Student’s
t test. All analyses were two tailed, conducted using Graph
Pad Prism (V 4.01), and applied a 95 % confidence level
(p\ 0.05).
Results
Over-expression of mutant full-length tau in L66
is characterised by intracellular tau fibrils
with a proteolytically stable repeat domain core, axonal
disintegration, and a prominent motor phenotype
General observations
The construct used for L66 (Fig. 1a) comprises the longest
tau isoform in the central nervous system (htau40; 441
amino acid residues) with four repeats and containing the
point mutations P301S and G335D. This was cloned into
the Thy-1 expression cassette and administered through
pronuclear injection. Founder lines (Fig. 1f) showed vari-
ous copy numbers of transgenes. Two of these were
examined further, Lines 36 (L36) and L66. The strongest
pathology was seen in L66 mice (e.g., see comparison with
Line 36, see Fig. 5d, e). Expression of mutated full-length
proteins was confirmed in brain homogenates by immu-
noblotting which showed a protein with gel mobility
corresponding to 70 kDa. This was recognised by a panel
of antibodies having epitopes spanning the length of the
protein (Fig. 1c), including a human-specific N-terminal
epitope recognised by mAb 27/499. By contrast, endoge-
nous mouse tau with gel mobility corresponding to 50 kDa
did not react with mAb 27/499.
Offsprings of L66 were healthy and developed normally
after birth. We did not observe any behavioural abnor-
malities upon cage-side assessment. However L66 mice
showed lower body weights by 4–7 months of age and this
reduction was more pronounced in homozygous mice
(Fig. 1e) compared with heterozygous mice. Homozygous
female mice frequently developed a palsy-like dyskinesia
that was apparent on inspection by the age of 6–7 months.
This did not curtail life expectancy or affect other daily
activities.
Immunohistochemical, neuropathological, ultrastructural
and biochemical characterisation of L66 mice
Brain tissue from both L36 and L66 mice had clearly
identifiable intracellular tangle-like tau immunoreactivity
using mAb 7/51 (which recognises an epitope in the repeat
domain) and mAb AT8 (which recognises a phosphoryla-
tion-dependent conformational epitope). These features
were seen in both cortical (Fig. 2a: CA1 and hilus) and
non-cortical (see Fig. 4 below) regions with both antibod-
ies. In addition, punctate staining in neuronal cell bodies,
extending into the proximal part of their axons (Fig. 2g),
was observed in L66 but not in L36. No staining was seen
with either antibody in any region in wild-type mice. That
is, although mAb 7/51 recognises an epitope in the repeat
domain which is also present in native mouse tau, the
antibody labels only pathological aggregates in both AD
brain tissues [38, 39] and in transgenic mouse models but
not in wild-type animals. Staining of normal tau in wild-
type brain tissue requires special fixation conditions [47].
Minimal to mild staining of the CA1, CA3 and hilar
neurones was observed with 7/51, but only few hilar neu-
rones were stained with AT8 (not shown). By contrast,
axonal staining was much more apparent with mAb AT8
(Fig. 2d). This was present multifocally within the brains
of all L66 mice. Many axons were characterised by a
discontinuous pattern of staining, suggesting a process of
axonal fragmentation.
Although the regions stained with mAbs 7/51 and AT8
were similar, there was also evidence of dissociation with
respect to neurons labelled and the region of the neuron
labelled. This is shown for example in Fig. 2g where
double-labelling has been used to demonstrate the exis-
tence of distinct neuronal populations labelled,
respectively, with mAb AT8 and mAb 7/51, with little
overlap. Therefore phosphorylation of tau, as seen with
mAb AT8, is not a necessary requirement for tau aggre-
gation detected using mAb 7/51 either in terms of neurons
labelled, or the location within the neuron where labelling
occurs.
Surprisingly, regional counts of histologically positive
neurones (using mAb 7/51) were greater in L66 at ages less
than 6 months than in mice aged 12 months or more
(Fig. 3a). The reasons for this observation are not clear but
confirm the absence of age-dependent spread of pathology
similar to Braak staging.
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Labelling with mAb AT8 in L66 was also associated
with axonopathy. Staining in frontal cortex was more
prominent than piriform cortex, parietal regions and
amygdala (not shown). Cerebellar axonopathy was evident
in cerebellar cortex and deep nuclei sections of L66
(Fig. 4a-i, iii), but also showed neuronal staining with mAb
AT8 (Fig. 4a-ii). No axonopathy in deep cerebellar nuclei
was found with mAb 7/51 (Fig. 4a-iv). Phospho-tau mAb
AT8 labelled neurones in both pontine axons and cells
(Fig. 4b-ii), but also more anterior thalamic nuclei
including the ventromedial thalamic nuclei and zona in-
certa (Fig. 4c-i) including subthalamic nuclei, the red
Fig. 1 Constructs used for microinjection and expression parameters
of protein for full-length mutant and truncated tau. a The L66 cDNA
construct contains human tau cDNA coding for the longest human
CNS tau isoform (htau40; 441 amino acids) with the point mutations
to make the amino acid changes P301S and G335D. b The L1 cDNA
construct contains human tau cDNA coding for amino acid residues
296–390 with signal sequence and related sequences in murine Thy-1
expression cassette. c Immunoblot analysis of 6-month-old WT (lane
1) and L66 (lane 2) mouse brains with recombinant truncated dGAE
(lane 3) and full-length htau40 (lane 4) for reference. The faint
25-kDa band seen in lane 1 was only seen with the wild-type mouse
brain and was observed when the secondary anti-mouse antibody was
used in the absence of primary tau antibody. The 70-kDa band reflects
full-length mutant tau and is detected by all of the antibodies shown.
Note that the 55-kDa band, that is not detected by the human-specific
mAb 27/499, represents endogenous mouse tau. The position of
markers indicates relative molecular mass (Mr) in kDa. d Immunoblot
characterisation of tau in 4-month-old L1 (even numbers) and WT
mice (odd numbers). Protein extracts from whole-brain lysates were
separated by SDS-PAGE and immunoblots stained with antibodies
7/51 and K9JA for epitopes within the repeat domain of tau.
Immunoreactive bands at 12- and 18-kDa (arrowheads) were detected
in L1 mice (lanes 2, 4, 6 and 8) but not in extracts from wild-type
animals (lanes 1, 3, 5 and 7). Antibodies for C-terminal (T46) and
N-terminal (27/342) epitopes did not react with these proteins. The
intense bands at 25- and 50-kDa reflect endogenous mouse antibody
chains detected by secondary antibody. e Reduced body weight in
female L66 cohorts (wild-type: n = 12 at 4 months; n = 24 at
6–7 months. L66?/-: n = 17 at 4 months; n = 13 at 6–7 months.
L66?/?: n = 17 at 4 months; n = 25 at 6–7 months). Mean ? SE;
*p\ 0.05, t test. f Southern blot to determine transgene copy number,
using genomic DNA of heterozygous founder mice of each line.
Hybridisation with DNA of approximately 5 kb corresponds to the
transgene, and 8.2 kb to WT tau. Lines 36, 44 and 66 carry the mutant
full-length tau construct (see in a); Lines 1, 86a and 86b carry the
short construct (see in b). The numbers of DNA copies incorporated
into the genome for each line are given. g Reduced weight at young
and increased weight at old age in female homozygous L1 mice (WT:
n = 42 at 5 months; n = 9 at 13 months; L1: n = 45 at 5 months;
n = 15 at 13 months). Values expressed as mean ? SE; *p\ 0.05,
t test
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nuclei and various layers of the superior colliculus
(Fig. 4e).
Similarly widespread was the amino cupric silver-posi-
tive staining for axonal disintegration encompassing the
frontal cortex and the external capsule, the white matter of
the caudate-putamen and the internal capsule (Fig. 4d).
White matter degeneration was particularly strong in the
lateral reticular nucleus of the rostral thalamus (not shown),
but also in the ventromedial thalamic nuclei extending into
the central portion of the thalamus (Fig. 4c-ii). Staining
was weaker in caudal thalamus and rostral midbrain,
mainly present in the medial lemniscus and adjacent
cerebellar peduncles. Within the caudal midbrain, strong
axonal staining was present in transverse fibres of the
pontine reticular region (Fig. 4b-i). At the level of the
cerebellum, prominent axonal cupric silver staining was
present in the deep cerebellar white matter (Fig. 4a-v), the
acoustic nerves and cochlear nuclei, the spinal trigeminal
tract and within the medulla oblongata.
Electronmicroscopic (EM) investigations were under-
taken in spinal cord from L66 mice because other tissues
were used for quantitative immunohistochemistry and
neuropathological investigations. EM revealed the accumu-
lation of abundant pathological filaments in L66 mice aged
Fig. 2 Tau immunohistochemistry of transgenic tau L66 (a, b, e, f,
i) and L1 (c, d, g, h) mice. Tau immunoreactivity with mAb 7/51 is
strong in L66 with prominent intracellular staining in the hilus/CA4
sectors of the hippocampus (a) and in other areas (see Fig. 4). In
contrast, mAb AT8 immunoreactivity is seen more frequently in
elderly mice with staining apparent in long processes of CA1 (d).
Neurons in visual cortex (g) are stained differentially with both mAb
7/51 (brown) and AT8 (red). Amorphous intracellular tau immuno-
reactivity, visualised using mAb 7/51, in the hilus/CA4 of L1 mice
(b) is much weaker than for L66, and absent from the corresponding
region in WT mice (c). The presence of pS404 phospho-tau
immunoreactivity was seen in hippocampus and cortex and was
more intense for L1 late in life. At 3 and 9 months old, L1 and WT
animals were similar. It was only at 15 months of age that a
prominent difference between L1 and wild-type was observed, with
CA1 labelling for pS404-Tau greater in L1 (e) than WT (f). The
staining of neurons with this mAb indicates that there are granular
accumulations of pS404-Tau immunoreactivity in long processes (h,
i). Scale bars 50 lm (a, d); 25 lm (e–g); 20 lm (b, c) and 10 lm (h,
i)
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8–9 months (Fig. 5b, c), that were absent from age-matched
wild-type mice (Fig. 5a). The appearance and distribution of
cytoplasmic organelles in the cell bodies appeared normal
and the pattern of axonal microtubules was regular in wild-
type mice (Fig. 5a). In contrast, large filamentous aggregates
were found in neuronal cell bodies in L66 that displaced
organelles such as mitochondria, Golgi apparatus and
endoplasmic reticulum (Fig. 5b). Areas containing filamen-
tous material were strongly labelled with immunogold
particles using a polyclonal anti-tau serum that does not
show phosphorylation-dependent immunoreactivity. By
contrast, there were only occasional gold particles detected
in cytoplasmic and nuclear areas without filaments (Fig. 5c),
and there was no immunogold labelling in wild-type mice
(not shown). The pathological filaments formed in L66 brain
tissues are biochemically PHF-like in that they contain a
proteolytically stable core restricted to the repeat domain
comprising only 3 repeats [1, 4, 48].
Both Bielschowsky silver and primulin staining con-
firmed that tau derived from mutant full-length transgenes
aggregates into filamentous structures in L66 (Fig. 5d–f)
and with a higher density than seen in L36 (Fig. 5e).
Intracellular aggregation was found in the somatodendritic
compartment of neurons.
Prominent age-dependent impairment in sensorimotor
performance and motor learning in L66
We observed numerous abnormalities with respect to gait
and walking patterns in L66 mice (Fig. 6). L66 animals
differed from wild-type mice in stride length (Fig. 6a;
F(3, 123) = 16.8, p\ 0.0001) with heterozygous and
homozygous mice having longer and shorter strides,
respectively. A similar difference occurred for the base of
support for both front and hindlimbs (Fig. 6c:
F(3, 50) = 11.6, p\ 0.0001 fore; F(3, 50) = 26.3,
p\ 0.0001 back). Relative paw position showed normal
positive values in wild-type mice but not L66 mice
(Fig. 6b; F(3, 123) = 6.2, p\ 0.0006). A marginal
reduction in regularity index was seen in homozygous L66
mice (Fig. 6d; F(3, 61) = 2.6, p = 0.06) but no difference
occurred for parameters related to step cycle (data not
shown). Surprisingly, L66 mice with prominent dyskinesia
did not show greater evidence of gait disturbance on these
parameters compared to those without.
On the balance beam, heterozygous L66 mice performed
similarly or better than wild-type controls (shorter latencies
for reaching the end of the beams). By contrast, homozy-
gous L66 mice were severely impaired (Fig. 7).
Furthermore, performance on the balance beam was sig-
nificantly worse in homozygous animals with dyskinesia
than in those without. These effects were observed for both
square (Fig. 7a; effect of genotype, beam size and inter-
action: F[ 9, p\ 0.0001) and round beams (Fig. 7b;
effect of genotype, beam size and interaction: F[ 11,
p\ 0.0001). Pairwise comparisons (using the Bonferroni
correction for multiple comparisons post hoc) yielded
numerous statistically significant differences with respect
to controls (see asterisks in Fig. 7a, b).
Motor performance (Trials 1 ? 2) was also investigated
on the RotaRod (Fig. 8). Whereas homozygous mice aged
4–5 weeks were not impaired in motor performance
(Fig. 8a), by 6 months of age they showed impairment
(Fig. 8d; effect of genotype: F(3, 125) = 22.5, p\ 0.0001;
Fig. 3 Quantitative regional and age-related tau immunohistochem-
istry of transgenic L66 and L1 mice. Tau-positive neurons reacting
with mAb 7/51 were quantified in homozygous L66 mice by region
(a) and by age (b). Data are presented as group mean log10 of the sum
across individual brain regions taken from Bregma -3.16 mm
according to the stereotaxic mouse atlas [43]. Young animals aged
\6 months presented with stronger immunoreactivity in all regions.
The cell count (group mean log10 ? SE) across all regions is already
high at 3 months (n = 2) and decreases substantially at 6 (n = 4) or
12 months (n = 5). A amygdala, AC auditory cortex, ERC entorhinal
cortex, Hip hippocampus, RSC retrosplenial cortex, S subiculum, VC
visual cortex. In contrast, for L1 mice (n = 6 for each age group)
there was a significant age-related increase in labelled cells in all
regions in older mice (c). Global cell count (group mean log10)
averaged across all regions (?SE) selected from the same level and
plotted as a function of age (n = 3 each). There was no difference in
tau immunoreactivity in animals aged 3 or 6 months, but pathology
increased at 12 and more so at 18 months (*p\ 0.05, ***p\ 0.001)
(d). There were approximately sevenfold more tau-positive neurons in
L66 relative to L1
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see asterisks for pairwise comparison with wild-type). The
level of impairment was not greater in homozygous L66
mice with dyskinesia compared to those without. Motor
learning was already impaired in homozygous L66 mice
aged 4–5 weeks (Fig. 8b; genotype x trial interaction:
F(11, 792) = 1.9, p = 0.04), and this deficit increased
considerably in 6-month-old cohorts (Fig. 8e; interaction:
F(33, 649) = 4.4, p\ 0.0001). Six-month-old heterozy-
gous mice were mildly impaired (F(11, 396) = 1.6,
p = 0.01). In homozygous L66 mice (Fig. 8d–f), the pre-
sence of dyskinesia was associated with further
enhancement of the deficit (dyskinesia effect:
F(11, 253) = 0.9, p = 0.05).
In addition, we assessed the amount of the learning
deficit at the end of training by comparing the difference in
improvement between first and last training trials. We
reasoned that severe learning deficits (for instance in
homozygous L66 mice aged 6 months) may preclude any
improvement relative to start of training. While all cohorts
showed significant improvements in performance in trial
12 relative to trial 1 (Fig. 8c, f; all p values\0.01 when
compared to 0), we established considerable differences in
the amount of learning between cohorts (see asterisks).
While heterozygote L66 mice presented with small
impairments at 6 months, deficits were more severe in
homozygous groups. Again, dyskinesia did not enhance
severity of the deficit relative to non-dyskinesic age-mat-
ched subjects (Fig. 8f).
Absence of cognitive-spatial deficits in L66 mice
Despite the abundance and severity of pathology seen in L66
mice, no cognitive phenotype was observed in the standard
version of the water maze (Fig. 9). Both L66 and wild-type
mice swam the same path length to find the platform and
attained identical performance on day 4; statistical analysis
Fig. 4 Distribution of aggregated tau in L66 transgenic mice.
a Staining for astrocytes and axons in the cerebellum of L66 mice
aged 6–7 months. a-i Cross-sections through the mid-cerebellar
region and underlying brainstem stained for GFAP in L66 shows
immunoreactivity within the cerebellar white matter (CW). Cellular
staining for phospho-tau using mAb AT8 (a-ii) was identified in both
the cerebellar cortex and in the deeper cerebellar nuclei (a-iii, CN),
but also some weak staining in processes running through the white
matter, and non-specific immunoreactivity in the Purkinje cell layer
(P). Deep nuclei were stained also with mAb 7/51, but no processes
were immunopositive (a-iv). Axons stained darkly by the amino
cupric silver stain indicate injury to axonal integrity in L66 mice (a-
v). b Degeneration of fibres and expression of human tau in pons and
ventral tegmentum. Axonal injury was observed in pons using amino
cupric silver staining (b-i). While black arrows indicate scattered
positivity for longitudinally oriented axons in tegmental regions,
strong labelling of transverse fibres (red arrows) occurred in the
cerebral peduncle. Somata/processes were also densely labelled for
phospho-tau using AT8 (b-ii) in both pontine axons and cells (red
arrow) and tegmental neurons (arrowhead). c Anterior thalamic
expression of tau. Dense AT8 labelling (c-i) was observed in cells and
axons of the ventrolateral thalamic nucleus (VL) and zona incerta (ZI)
with more scattered immunoreactivity in the centro-medial nucleus
(CM) concentrated to the cell soma. Phospho-tau labelling overlapped
with axonal injury as revealed by amino cupric silver staining (c-ii)
and was most clearly visible in VL and CM. d Basal ganglia
axonopathy in L66. The coronal section is stained with amino cupric
silver and magnified to reveal axonal degeneration in both the
external capsule (EC; arrowheads) and caudate-putamen (CP;
arrows). e Low magnification micrograph of the cross-section
through the L66 midbrain labelled with AT8. Prominent cellular
and axonal phospho-tau labelling occurred in the red nucleus (R) and
deeper layers (DL) of the superior colliculus with processes reaching
towards the dorsolateral superficial layers (SL). Scale bars a-i, a-ii
1 mm; a-iv, b-ii, c-i, c-ii, e 0.5 mm; a-iii, a-v, b-i, d 100 mm
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confirmed learning (main effect of trial day: F(4, 88) = 4,
p = 0.005), but no effect of genotype (Fig. 9a). Moreover,
there was no difference in swim speed (Fig. 9b). Although
genotype and day interacted with respect to time spent in the
thigmotaxis zone (Fig. 9c; F(3, 66) = 4.7, p = 0.005), this
difference was transient and only occurred during the initial
2-day acquisition period. Furthermore, L66 mice presented
with a strong spatial bias in the probe trial (Fig. 9d),
spending more time in the target quadrant, as was seen also
with wild-type controls. Therefore, L66 showed evidence of
normal acquisition learning of the standard spatial discrim-
ination task.
Over-expression of the truncated PHF-core repeat
domain fragment of tau in L1 is characterised by non-
fibrillar tau pathology associated with a prominent
cognitive phenotype and minimal motor features
The truncated repeat domain fragment of tau corresponding
to residues 296–391 or its homologues in other tau
Fig. 5 Filamentous tau in L66. Electronmicroscopy of spinal cord
from a WT and b L66 mice and c anti-tau immunoelectronmicros-
copy of L66. Dense bundles of filaments were found in large neurons
in L66 but not WT mice and these were immunodecorated with gold
particles labelling tau. The lower panel of images are selected
magnifications from the upper panel as indicated; scale 5 lm (solid
bars) and 0.5 lm (open bars). Bielschowsky silver staining for tau
aggregates was more abundant in cortical sections from L66 (d) than
L36 (e) mice. In addition, Primulin-stained neurons provide further
evidence of the formation of filamentous tau aggregates in cortical
tissue from L66 (f)
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isoforms is the predominant constituent of the core of the
PHFs found in the neurofibrillary tangles of AD. However,
constitutive or transient overexpression of this fragment in
cells is highly toxic. As reported elsewhere, we have shown
that the addition of an N-terminal signal sequence which
targets the protein to the ER membrane has the benefit of
ameliorating toxicity whilst nevertheless retaining the
ability to aggregate, and to both recruit normal tau into the
aggregates and induce its template-directed truncation [48].
We used this construct, therefore, to generate the trans-
genic L1 mouse.
General observations
Details of the generation of L1 mice are shown in Fig. 1.
The short construct (Fig. 1b) coding for amino acids
296–390 was cloned into a Thy-1 expression cassette and
injected into NMRI oocytes. Numerous founders were
identified (Fig. 1f) and Southern blot revealed a high
number of integrated transgenic copies in L1 (27 copies)
relative to all other transgenic lines of this construct. A
further line (Line 86b) had integrated 2 transgenic copies.
Expression of the truncated tau fragment was confirmed by
immunoblotting for L1 only. The transgenic protein was
found at low levels in brain homogenate and had gel
mobilities corresponding to 12- and 18-kDa. This fragment
reacted with repeat domain-specific antibodies mAb 7/51
and K9JA, but not with antibodies recognising epitopes
located in the N- or C-terminal domains of tau (Fig. 1d).
These 12- and 18-kDa bands were absent in brain
homogenates from wild-type (WT) mice.
Homozygous L1 mice had lower body weights at
5 months of age (t = 2, p = 0.04; Fig. 1g), but gained
weight more rapidly to exceed the weight of wild-type
mice by the age of 13 months (t = 2.6, p = 0.01). The
animals tended to be hyperactive and showed enhanced
freezing in novel environments.
Immunohistochemistry of L1 shows age-dependent spread
of tau-aggregation pathology similar to Braak staging
Immunohistochemical staining with mAb 7/51 was wide-
spread and mainly localised to neuronal somata in
hippocampus (Fig. 2b) throughout cortex, and also in
Fig. 6 Gait analysis of transgenic L66, L1 and wild-type mice using
the CatWalk. Left Aged 6–7 months, four different female groups of
L66 were tested: (1) WT, n = 24; (2) L66?/-, n = 14; (3) L66?/?
with dyskinesia, n = 12; (4) L66?/? without dyskinesia, n = 13.
Note that animals with palsy-like dyskinesia did not perform different
from non-dyskinetic littermates. While heterozygous L66 mice
presented with longer stride length, L66?/? mice had reduced length
of footfall with no difference between front or hind paws (a). WT
showed the NMRI-typical positive overlap with hind paws falling
behind forepaws, L66 had generally no overlap (b) or fell signif-
icantly in front of forepaw (a negative value implicates that the
hindpaw is placed upward with respect of the forepaw and conversely,
a positive value indicates that the hindpaw is placed backward
compared to the forepaw). In general, all genotypes had greater base
of support (BOS) for hindlimbs and, while heterozygote mice tended
to have wider gaits, homozygous groups brought front and hind paws
closer together (c). This may have led to a lowering in the regularity
index (RI). The RI grades the degree of coordination and represents
the percentage of regular step patterns in which the paws are placed
on the glass plate—alternate patterns (i.e. Aa and Ab) and cruciate
patterns (i.e. Ca and Cb) (d). Right Homozygous L1 female mice and
WT were compared (n = 14 each) at 5–6 months. Stride length
(mean of front and hind paws) was greater in L1 mice (e), but both
WT and L1 placed hind paws behind the front paws (f: positive
values). The overall base of support was not affected for front, but
higher for L1 hind paws (g). A small increase in RI (h) but no
significant difference in axial or cruciate paw placements was
revealed. All data expressed as group mean ? SE; *p\ 0.05, t test.
$Difference from WT and L66?/- groups
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spinal cord and cerebellum (not shown). Line 86b, by
contrast, was devoid of labelling even at 18 months and no
labelling was seen in wild-type controls (Fig. 2c). The tau
immunoreactivity was typically amorphous in character,
with no evidence of formation of tangle-like structures. In
particular, there was no staining with Bielschowsky silver,
primulin or thioflavin S (not shown). Although there was
already weak labelling with p-Tau (S-404) (which labels a
C-terminal phospho-serine epitope) in wild-type animals,
this was greatly accentuated in L1 mice only by 15 months
(Fig. 2e, f). The labelling was seen in cortical neurons at
15 months (Fig. 2h, i). No labelling was seen with the
phosphorylation-dependent mAb AT8. Therefore, tau
aggregation seen in L1 mice was halted at the amorphous/
oligomer stage and did not progress to formation of path-
ological filaments or neurofibrillary tangles, and was not
associated with increased phosphorylation of endogenous
tau until later life.
Quantitative analysis of immunohistochemistry was
undertaken using mAb 7/51 (Fig. 3c, d). In L1 mice aged
3–6 months, the log count of neurons labelled was 14 % of
the number labelled with mAb 7/51 in L66 for all regions.
At this age, labelling was restricted primarily to entorhinal
cortex and hippocampus, with minimal labelling in neo-
cortical regions. In older animals aged 12–18 months,
labelling increased in hippocampus and entorhinal cortex,
and most notably spread to retrosplenial cortex, subiculum
and visual cortex. Thus L1 mice showed the characteristic
pattern of progression that is seen as Braak staging in
Alzheimer’s disease.
Minimal sensorimotor deficits in L1 mice at 3 and 6 months
Unlike L66, L1 mice did not show any gross motor
abnormality on cage side observation. When investigated
further, only mild differences in gait were observed, being
seen as an increase in stride length (Fig. 6e), hindlimb base
of support (Fig. 6g), and regularity index (Fig. 6h). Rela-
tive paw position (Fig. 6f) did not differ from wild-type
mice.
Also in marked contrast to L66, L1 mice showed better
performance on the balance beam task than wild-type
controls. Independent of beam shape (genotype factor:
square Fig. 7c: F(1, 52) = 10.3, p = 0.004; round Fig. 7d:
F(1, 52) = 4.5, p = 0.04), L1 mice were faster to reach
the end of the beam, but all animals found the smaller
Fig. 7 Differential phenotypes for L66 (a, b) and L1 (c, d) on the
balance beam and in the light/dark box tests (e, f). For heterozygous
L66 mice (6–7 months), while performing equally or better than age-
matched controls at 5- or 12-mm beams, deficiencies were observed
in homozygous females, which were impeded at all beams (a, b).
Note that animals with dyskinesia performed worse than normal age-
matched homozygous mice (WT n = 24; L66?/- n = 14, L66?/?
n = 25). For 5- to 6-month-old L1 mice, latency to traverse square
beams was shorter (better performance) than wild type (n = 14 each,
females) (c). There was a similar finding for L1 with round beams (d).
Increase in latency for the more difficult beams reflects the more
challenging nature of small beams. In the light/dark box test, L1 and
control mice aged 7–8 months (WT n = 13; L1 n = 13) spent similar
amounts of time in the dark compartment (e) and presented with
comparable number of entries (f). Values expressed as mean ? SE;
asterisks denote group differences (Student’s t test) at p\ 0.05.
^Statistically significant difference from all the other groups; $differ-
ence from WT and L66?/- groups
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beams more challenging (beam factor: F[ 14,
p\ 0.0001). Nevertheless, L1 mice still performed better
on the smallest beam than wild-type controls (t = 2.46,
p\ 0.05).
We investigated the possibility that a lowering of anx-
iety might contribute to this behavioural enhancement, but
were unable to find any anxiety-related phenotype using
the light/dark box. There was no difference in time spent in
the dark compartment (Fig. 7e) or the number of entries
between light and dark chambers (Fig. 7f: all p values
[0.2).
Despite faster climbing on beams, L1 mice were
impaired in motor coordination and learning on the Ro-
taRod task. When placed on the rotating rod, L1 mice fell
off earlier during the first two trials (gene factor: t = 4.2,
df = 54, p\ 0.0001) than did wild-type mice (Fig. 8g).
This suggests a difficulty in movement and step progres-
sion in line with the accelerating rod. L1 mice were also
slower in acquiring the RotaRod learning task, lagging
behind wild-type controls in terms of time on the rotating
rod, but nevertheless showing improvement over succes-
sive trial days (Fig. 8h; gene factor: F(1, 286) = 15.8,
p = 0.0005). Indeed, the overall gain after 12 trials rela-
tive to trial 1 did not differ (Fig. 8i), suggesting
equivalent motor learning, albeit at an impaired overall
level.
Prominent cognitive-spatial deficits in L1 mice at 3
and 6 months
Cognitive phenotyping of L1 mice in the open field water
maze was undertaken using two different paradigms. In the
Fig. 8 Female tau mice show deficits in motor coordination and
motor learning. Top row (a, d, g) Latency to stay on the accelerating
RotaRod in Trial 1 and 2 as an index for motor coordination. L1 mice
(g 5–6 months; WT n = 14; L1 n = 14) were significantly impaired,
as were homozygous L66 (d 6 months; WT n = 24, L66?/- n = 14;
L66?/? n = 13; L66?/? dysk. n = 12), but not L66 aged 4–5 weeks
(a WT n = 40; L66 n = 34). Heterozygous L66 did not present with
a phenotype up to 6 months. Middle row (b, e, h) Motor learning on
the RotaRod over 12 trials (3 days of 4 trials) was impaired in all
transgenic cohorts including L1 (h), as well as homo- and heterozy-
gous L66 at 4–5 weeks (b) or 6 months (e). Bottom row (c, f,
i) Overall performance gain between trial 1 and 12 in different
cohorts. Despite a performance deficit in L1, the overall amount of
improvement was not different to controls (i). Similarly, all L66
cohorts had significant learning different from 0 (not indicated), but
L66 mice typically improved less than WT both at 4-weeks (c) and
6 months (f). Values expressed as mean ± SE; asterisks denote group
differences (Student’s t test) at p\ 0.05
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first paradigm, we administered a standard reference
memory test with constant platform locations over 4
training days (Fig. 9). One wild-type mouse was excluded
for continuously poor performance not improving over the
course of training. Already at 3 months of age, L1 mice
were impaired in acquisition learning as indicated by a
Fig. 9 Spatial learning deficits are absent in L66 transgenic mice but
observed in L1. Standard open field water maze acquisition learning
and recall are shown for L66. No spatial phenotype was observed in
L66?/? mice aged 4 months (a–d WT n = 12; L66?/? n = 13).
There were no differences in path length (a) and swim speed (b), but
lower levels of thigmotaxis occurred on the first 2 days of training
(c see asterisks for p\ 0.05). Also, there was no deficit in recall
indexed as quadrant time (d). Standard open field water maze
acquisition learning and recall are shown for cohorts of L1 mice aged
3 months (e–hWT n = 9; L1 n = 10) and 6 months (i–lWT n = 10;
L1 n = 13). Three-month-old L1 mice need longer swim paths to find
the hidden platform (e), but eventually acquire the spatial task after 24
trials (day 4). Note that there was no difference in path length in trial
1, but a strong retardation in learning. Young L1 mice swam faster
throughout acquisition (f), but thigmotaxis was not significantly
enhanced (g). Recall (time in quadrant) tested 1 h post-training was
deficient in L1, but there was a weak tendency for the target quadrant
in controls (h). Deficits in 6-month-old L1 mice were more
pronounced. Transgenic mice failed to acquire the spatial task (i),
swam considerably faster (j) and maintained high levels of thigmo-
taxis (k) relative to age-matched controls. Consistent with the failure
to acquire the task, there was no spatial bias for the target quadrant in
L1 subjects (l) whereas controls developed strong memory for the
platform location. All data represent mean ± SE. Asterisks indicate
*p\ 0.05, **p\ 0.01, ***p\ 0.001, ****p\ 0.0001 for group
comparison; #p\ 0.05 relative to chance. Insets depict representative
swim paths for the last acquisition trial on day 4 (top row) and during
probe test (bottom) for WT (left) and L66 or L1 (right)
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longer daily path length to reach the hidden platform
(Fig. 9e; gene factor: F(1, 68) = 11.8, p = 0.003). Both
genotypes improved over days (day factor: F(4, 68) = 2.8,
p = 0.03) and reached the same performance level at day
4. There was no evidence of sensory motor deficit, as both
groups performed equally in trial 1 (t = 0.6, p = 0.5). L1
mice always swam faster than controls (Fig. 9f;
F(1, 63) = 22.5, p = 0.0001) but showed normal thigmo-
taxis (Fig. 9g; F = 1). In the probe test, when the target
platform was removed, wild-type controls clearly preferred
the target over non-target quadrants (Fig. 9h; t = 3,
p = 0.01), but the L1 mice did not. However, this differ-
ence was not statistically significant at 3 months, due to
high variability (F = 2.5, p = 0.24; F test).
The cognitive deficits became more pronounced at
6 months (Fig. 9i–l). A single wild-type mouse presented
with circling behaviour and was excluded from the ana-
lysis. L1 mice were consistently impaired and swam longer
paths to reach the platform (Fig. 6i; gene factor:
F(1, 80) = 18, p = 0.0004), but were not significantly
different in first trial (t = 2.1, p = 0.08). Both genotypes
improved their performance throughout training (day fac-
tor: F(4, 80) = 9.9, p\ 0.0001) and differed significantly
on day 4 (t = 3.9, p\ 0.001). As already indicated at
3 months, 6-month L1 mice swam faster throughout
(Fig. 9j; gene factor: F(1, 60) = 26.3, p\ 0.0001). They
became more thigmotaxic than at 3 months (Fig. 9k; gene
factor: F(1, 60) = 11.8, p = 0.003). In the probe test,
when the platform was removed, wild-type mice were
spatially biased towards the target quadrant over non-target
quadrants (t = 5.1, df = 16, p\ 0.0001) whereas L1 spent
equal times in all quadrants (Fig. 9l). These data demon-
strate spatial learning and memory difficulties in L1 mice
that begin at 3 months and progress in severity by
6 months.
We used a second paradigm to investigate the spatial
learning deficit further at 3 months and 5–6 months in
separate cohorts of female L1 mice and wild-type controls
using a problem solving task in the water maze (Fig. 10).
This entailed a visual training over 4 days with platform
location shifting between days. Although 3-month-old L1
mice required a longer path to find the platform on day 1
(Fig. 10a; gene factor: F(1, 88) = 10, p = 0.004) there
was no difference for the first and last trial of training.
Again, L1 mice swam faster in all trials (Fig. 10b; gene
factor: F(3, 66) = 17, p = 0.0004). Each animal was then
required to find the platform in less than 20 s in three
consecutive trials. Once the criterion was met, the plat-
form was moved to a different position and training
progressed until criterion was met for three problems. L1
mice at 3 months required more trials to achieve criterion
when averaged across all problems (Fig. 10c; t = 3.4,
df = 110, p = 0.0009). Although L1 mice performed
worse in all problems, they improved continuously
throughout training, but this only reached significance for
problem 1 (Fig. 10d; t = 2.2, df = 22, p = 0.037).
However, all animals managed to acquire all problems
within the given number of ten sessions (Fig. 10e). At age
6 months, L1 mice required longer paths to learn the
visible phase of the task (Fig. 10f; gene factor:
F(1, 208) = 33.5, p\ 0.0001) but did not differ at day 4
from wild-type controls. Transgenic mice swam consis-
tently faster (Fig. 10g; gene factor: F(1, 156) = 75.2,
p\ 0.0001) and required on average about twice as many
trials to attain criterion compared with wild-type mice
(Fig. 10h; t = 5.4, df = 154, p\ 0.0001). At 6 months,
L1 mice were deficient in all problems (Fig. 10i; t[ 2.4,
p\ 0.05) and only 82 % of L1 transgenics completed the
task (Fig. 10j). These data confirm a severe deficit in
spatial learning in L1 mice which progresses with age
from 3 to 6 months.
Discussion
We report a comparison of endophenotypes of two
transgenic mouse lines overexpressing different tau
protein constructs using similar promoters. L66 mimics
existing FTDP-17 lines by the inclusion of a P301S point
mutation, albeit with an additional G335D mutation
which enhances tau aggregation in vitro (data not
shown). L1 on the other hand is based on the truncated
repeat domain tau fragment which accounts for 95 % of
tau protein content of PHFs in AD [28]. Although both
models are based on overexpression of tau protein, there
are major differences in the resultant neuropathological
and behavioural phenotypes. In common with previously
reported models based on mutant forms of full-length
tau, the phenotype in homozygous L66 mice is charac-
terised by an early onset of sensorimotor deficits, gait
anomalies and learning deficits restricted to the motor
domain, all of which become more severe as mice age. It
culminated in a palsy-like dyskinesia at the age of
7 months resembling Parkinsonism in FTDP-17. Note-
worthy is the complete absence of a higher cognitive
phenotype in L66 despite the severity of neuropatho-
logical changes present. By contrast, L1 mice display
deficits in spatial learning resembling the difficulties in
forming memories within spatio-temporal contexts in
AD [49]. These changes are associated with minimal
abnormalities in sensorimotor function. There is there-
fore a marked dissociation between cognitive and
sensorimotor expressions of tau-aggregation pathology
that depends solely on the form of tau which is over-
expressed in the absence of APP overexpression or b-
amyloid pathology.
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Pathological and biochemical differences between L1
and L66 mice suggest different but convergent
pathways of molecular pathogenesis
We determined, for several transgenic lines generated with
both full-length and truncated constructs, the number of
cDNA copies integrated into the host genome after pro-
nuclear injection. Despite having a large copy number and
expressing mAb 7/51-reactive truncated tau protein in
neurons of L1 mice expressing SStau296–390, the apparent
level of protein remained low and we did not observe
Bielschowsky- or thioflavin-positive neurons. Indeed, there
is a lack of overt fibrillary tau aggregates by conventional
histological criteria in L1 mice up to an age of 18 months.
We have not undertaken an ultrastructural analysis of these
aggregates, but they appear similar histologically to those
we have previously reported in AD [50]. Such early pre-
tangle aggregates of truncated tau are likewise amorphous
in character, and at an ultrastructural level are often asso-
ciated with mitochondria and ER [51, 52]. Overexpression
Fig. 10 Spatial problem solving task confirms cognitive impairment
in L1 tau transgenic mice at 3 months of age (a–e WT n = 10, L1
n = 14) and at 5–6 months (f–j WT n = 27; L1 n = 27). a Latency
to reach visible platform during 4 days of learning (4 trials/day).
Platform positions were changed in each trial. Note that L1 mice were
slow to acquire the task on day 1 (trials 2–4; ***p\ 0.001), but not in
the initial trial or the following days. b L1 mice swim faster than
wild-type controls on all days of the cued training. c Trials to criterion
averaged across all three problems. WT mice need fewer trials to
meet criterion than L1 mice. d Trials required to meet criterion for
problem 1 (top), problem 2 (centre) and problem 3 (bottom). For all
problems, WT mice achieve criterion faster than L1 mice, but this was
only significant for problem 1 and the impairment was less obvious
for problems 2 and 3. e Percentage of wild-type and L1 animals that
meet criterion for problems 1, 2 and 3 in the pre-set time. At this age,
all animals achieved criterion and the 2 week training period was
sufficient to solve all problems. f Latency to reach visible platform.
Note that L1 mice differed from WT on all days apart from trial 1 and
day 4, when they reached asymptotic levels of performance.
g Differences in swim speed recorded during the cued training were
apparent for all days with L1 mice swimming significantly faster
throughout. h Trials to criterion averaged across all three problems in
5- to 6-months-old mice. WT mice acquire criterion much faster than
L1 mice. i Trials required to meet criterion for problem 1 (top),
problem 2 (centre) and problem 3 (bottom). For all problems, WT
mice achieve criterion significantly faster than L1 mice. j Percentage
of wild-type and L1 animals that meet criterion for problems 1, 2 and
3 in the predetermined time. By 5–6 months of age, all wild-type
animals solved the three problems, whereas only 82 % of L1 did.
Values expressed as group mean ? SE. Asterisks indicate *p\ 0.05,
**p\ 0.01, ****p\ 0.0001
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of a substantially longer truncated construct (tau1–391)
likewise reached only the pre-tangle stage of pathology in
mice [53]. This suggests that tau protein needs to include
the C-terminal domain to achieve the configuration nec-
essary for filament assembly.
A particularly striking feature of the tau-aggregation
pathology seen in L1 is its anatomical progression out of
the entorhinal cortex and hippocampus at 3–6 months of
age into retrosplenial cortex, visual cortex and subiculum
at 12–18 months. This progression from archicortex into
neocortex is typical of Braak staging in AD. The highly
stereotyped neuroanatomical spread of tau pathology is
now understood in terms of transmission of tau aggregates
at the oligomer stage between neurones [7–12]. We have
previously reported that template-directed proteolytic pro-
cessing of tau protein leading to amplification of repeat
domain aggregates is a property inherent to the repeat
domain of tau which can be demonstrated in vitro in both
cell-free and cell-based models [6, 48]. The present dem-
onstration of the same phenomenon in vivo using a tau
construct restricted to the repeat domain further extends the
earlier findings. The neuroanatomical spread of pathology
in L1 is in marked contrast to the anatomically static nature
of the L66 pathology. The only previous report of neuro-
anatomical spread similar to Braak staging has been in
PS19/PDAPP mice [1, 21], with an early transentorhinal
stage in animals under 4 months, followed by a limbic
stage (4–10 months) and then an isocortical stage
([11 months). The present results show that concomitant
expression of mutant APP is not necessary for neuroana-
tomical spread of this kind, and that this property is
inherent to the repeat domain of tau.
In contrast to L1, and despite having only two transgene
copies, L66 was characterised by abundant intracellular
aggregates of tau recognised by mAb 7/51. The aggregates
could be stained both by the Bielschowsky stain and by
primulin consistent with progression of aggregation to the
filamentous stage [50]. This was confirmed by electron
microscopy of aggregates having the same histological
properties in spinal cord. By comparison L36 and hetero-
zygous L66 mice showed much weaker immunoreactivity
per neuron and had fewer tau-positive neurons overall.
Therefore the extent of tangle pathology is dependent on
gene dose in mutant full-length tau models. Compared with
the counts of tau-positive neurones in L1, those seen in
homozygous L66 mice are substantially more numerous.
Given the much higher copy number for the transgene in
L1 the most likely explanation for this difference is much
greater clearance of truncated tau directed to the ER by the
signal sequence. The pathology identified by mAb 7/51 in
L66 also has a much more widespread regional distribution
than L1, including midbrain and spinal cord, as well as
cortex and basal forebrain. The highest mean counts in L66
were in hippocampus, entorhinal cortex and retrosplenial
cortex. Surprisingly the tau-positive neuron count had
already attained a steady state level by 3 months, and
decreased substantially with age. This could be due either
to tangle-mediated neuronal destruction or age-related
adaptation to the transgene leading to enhanced clearance.
Whatever the reason, the neuranatomically static nature of
the tau pathology in L66 is in marked contrast with the age-
dependent neuroanatomical spread observed in L1.
In L66, prominent staining of axons was seen with the
phosphorylation dependent mAb AT8. This was not seen
with mAb 7/51 which tended to be more restricted to cell
bodies and apical dendrites, the typical distribution of
PHFs in AD. Although there was a general tendency for
regions and cells to be labelled by both antibodies, more
detailed analysis showed that there was limited overlap
between the two. This was demonstrated by double label-
ling in L66 mice, where only a subset of neurons with tau
aggregates detected with mAb 7/51 were also labelled with
mAb AT8. The same phenomenon was demonstrated in
aged L1 mice using p-Tau (S-404). Whereas no pS404
immunoreactivity was seen in younger animals, labelling
was seen in mice at 15 months in both neocortex and
hippocampus. Since the epitope in question is lacking in
the transgene, terminating as it does at Ala-390, acquisition
of pS404 immunoreactivity implies that both recruitment
of endogenous mouse tau and secondary phosphorylation
occur only after aggregation has been initiated. One-to-one
recruitment of native tau by truncated tau aggregates has
been reported previously in rats expressing a longer trun-
cated tau transgene (residues 150–390; [33]).
The implied dissociation between tau aggregation and
tau phosphorylation has important theoretical implications,
since it is commonly thought that hyperphosphorylation is
on the critical path to both aggregation and loss of
microtubule-binding function [54]. We have shown previ-
ously that, although the quantity of phosphorylated tau in
PHF preparations from AD brain is correlated with the total
quantity of aggregated tau, phosphorylated tau accounts for
less than 5 % of the tau content of the PHF in AD. We have
also shown that phosphorylation inhibits tau–tau binding
through the repeat domain by a factor of 20- to 50-fold
in vitro [55] in line with other reports [5, 28, 56, 57]. As we
have argued elsewhere, on the basis of data from human
brain tissues, phosphorylation of tau is likely to be a late-
stage epiphenomenon in the process of tau aggregation [5,
28]. This is now supported by the L1 transgenic mouse data
where tau phosphorylation is seen only after 15 months. In
L1, therefore, tau phosphorylation cannot explain the
severe cognitive deficits we have documented from
3 months of age.
The prominent axonal staining with mAb AT8 in L66
has been reported previously in other four-repeat tau
2216 V. Melis et al.
123
transgenic mice [58, 59]. A similar pattern of argyrophilic
axonal staining has been reported in rats subjected to
experimental blast injury [60]. In these rats, it was con-
sidered that the pattern of staining (i.e., with a predilection
for deep cerebellar white matter) represented a manifesta-
tion of the physics of the air blast shock wave. Based on the
findings in amino cupric silver-stained sections from L66
mice, it is possible that the pattern of axonal staining may
indicate that axons in certain brain regions are inherently
more susceptible to degeneration following a variety of
stresses. Hyperphosphorylation of tau is known to be a
non-specific response to a number of stressors in cell
models [61, 62].
The comparison of the L1 and L66 phenotypes at the
biochemical and pathological levels demonstrates the exis-
tence of two distinct but convergent pathways for the
pathological processing of tau protein. These are summarised
in Fig. 11. In L1, although pathology is arrested at the oli-
gomer stage, the model nevertheless demonstrates the key
features AD, namely prominent cognitive impairment and
age-related neuroanatomical spread of pathology of the type
formalised as Braak staging. We conclude that oligomers
consisting of the truncated repeat domain fragment of the
PHF core are the fundamental toxic species required for both
phenomena. The low levels of tau pathology, despite high
copy number, most likely represents enhanced clearance of
the SStau296–390 via the endosomal-lysosomal pathway.
This can be contrasted with L66, in which there is early
aggressive formation of filamentous neurofibrillary tangles
with high levels of pathology in entorhinal cortex and hip-
pocampus occurring in the absence of either higher cognitive
deficit or neuroanatomical spread of the Braak staging type.
In agreement with others [63, 64], this filamentous/tangle
stage of tau protein aggregation is not a critical driver of
clinical dementia, although it is linked quantitatively to
dementia [18] and eventual tangle-mediated neuronal loss at
advanced stages [65]. Hyperphosphorylation of full-length
tau is not required for cognitive impairment, interneuronal
transmission of pathology, assembly of PHFs or formation of
neurofibrillary tangles, but, in a non-aggregating form,
appears to be closely linked to disintegrative axonal degen-
eration. Both pathways involve recruitment of normal tau.
Both pathways converge at the point of formation of aggre-
gates in which the proteolytically stable core consisting of a
repeat domain fragment is restricted to approximately 3
repeats irrespective of either the transgene or the endogenous
tau which is recruited.
Different learning and sensorimotor impairments in L1
and L66
There was a striking difference in deficits in higher cog-
nitive function between L1 and L66. We employed two
different water maze paradigms including a standard open
field reference memory task commonly used for tau mice
(e.g., [66]) and a problem solving task [46, 67, 68]. The
spatial problem solving paradigm is analogous to the
delayed-matching-to-place (DMP) task and both have been
proposed as behavioural models of working/episodic-like
memory in rodents [46, 69, 70]. While the platform was
changed daily in the DMP task so that spatial information
is useful only for a short period (i.e., one trial), problem
solving consisted of repeated acquisition learning of a new
platform location to a level meeting a pre-set criterion.
Consequently, the spatial information is used for more than
a single trial and does not formally fit the classical defi-
nition of the ‘‘working memory’’ task [71]. The existence
of a strong long-term memory component in the problem
solving task makes it more akin to long-term ‘‘episodic’’
memory [72]. Early stages of AD display difficulties in
forming new memories of events within specific spatio-
temporal contexts and are the earliest and perhaps the most
sensitive sign of AD [49]. It is particularly striking that L1
mice already exhibited prominent cognitive deficits by the
early age of 3–4 months, and these deficits became more
severe at 5–6 months. At this time, tau-aggregation
pathology was largely restricted to entorhinal cortex and
hippocampus. Conversely, despite the presence of much
more extensive pathology in the same regions in L66
homozygous mice at 3 and 6 months, there was no evi-
dence of impairment on the spatial memory task. Several
other mouse tau models over-expressing P301S [73],
P301L [66, 74] or V337M [75] have also failed to show
spatial deficits in the water maze at ages when tangles
could be readily detected. On the other hand, truncated tau
gene expression in rats was also found to compromise
spatial cognition at 4–5 months [33], although the pheno-
type is confounded at older ages by the emergence of
severe motor deficits. The presence of early higher cogni-
tive deficits in both truncated tau models argues that
overexpression of a truncated tau fragment containing the
repeat domain is an important determinant of cognitive
impairment. Indeed, it appears to be more important than
high tangle counts in hippocampus and entorhinal cortex,
which are substantially higher in L66 than in L1 but
without causing higher cognitive deficits.
In addition to the severe deficits in spatial cognitive
function in L1 mice, there was also a performance deficit in
the RotaRod reminiscent of a global motor impairment.
However, their learning curve and overall improvement
during training did not differ from controls (Fig. 8). By
contrast, in L66 there was no motor impairment (with the
exception of elderly, homozygous mice developing palsy-
like dyskinesia), but a severe impairment in motor learning.
There is therefore an inverse dissociation between the two
transgenic mouse lines. Spatial learning in the water maze
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was impaired for L1 mice, but L66 mice were normal.
Conversely, L66 mice were severely impaired in motor
learning, but for L1 mice there was no difference in motor
learning relative to wild-type animals. These results con-
firm earlier reports showing that motor dysfunction [25,
76], increased exploration [77] and impairment of motor
learning [66, 78, 79] are common phenotypes for FTDP-17
models.
There were likewise marked differences in sensorimotor
function in L1 and L66. Six-month-old L1 mice displayed
shorter latencies to traverse all square/round beams when
compared to age-matched wild-type controls. This finding
is also in agreement with the results from young transgenic
rats expressing human truncated tau (tau151–391), which
were unimpaired in beam walking when 4–6 months old,
but progressed to sensorimotor disturbances at the age of
Fig. 11 Schematic representation of the molecular pathogenesis for
tau in L1 and L66 transgenic mice. In L1 mice, a generally toxic
truncated tau species can assemble into aggregates of small oligomers
of tau either on its own or via membrane-anchored species targeted to
the endoplasmic reticulum membrane when expressed as a fusion
with a signal sequence. These oligomers impair cognition already at
3 months and this progresses with age. At later stages, the aggregation
pathology can be transmitted in a Braak stage-like fashion to
neighbouring neurons which spreads and amplifies the pathology.
Phosphorylation of endogenous N-terminal tau that is recruited to the
pathological cascade is a late-stage event. A balance between toxicity
of truncated tau oligomers and their proteolysis and clearance is
required by the mouse for survival. L66 is characterised by an early
onset of aggregate and filament formation that is accelerated by the
presence of mutations within the PHF-core domain. There are sub-
populations of neurons which accumulate filamentous aggregates of
tau that consist predominantly of truncated 14-kDa tau oligomers
whereas others become phosphorylated, lead to axonal degeneration
but do not progress to PHFs. L66 mice are characterised by prominent
sensorimotor deficits
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9 months [33]. Similar observations were reported for
young tau-P301L transgenic mice vis-a-vis synaptic plas-
ticity and recognition memory [80] and here we report that
heterozygous L66 mice carrying the P301S/G335D muta-
tions also exhibited shorter latencies, especially when
tested on small beams. By contrast, homozygous L66 mice
with and without dyskinesia were severely impaired. It thus
appears that the occurrence of sensorimotor phenotypes is
dependent both on the dose of gene expression and the type
of tau expressed.
Interestingly, the observation of better performance in
the balance beam test was coincident with similar changes
in gait in L1 and L66 heterozygous mice, with longer stride
length and wider hindlimb gait present in both lines.
Homozygous L66 mice, on the other hand, show a reduc-
tion in these parameters. No comparative data from other
tau models are available here, but since the weight or size
of L1 and L66 cannot explain these contrasting findings, it
is reasonable to suggest that weaker tau expression (be it
truncated or full length) may provide some benefits to
sensorimotor function. Alternatively, shorter latencies to
traverse rods in L1 mice may reflect a hyperactive behav-
ioural profile also seen in heightened swim speed in the
water maze. Tau transgenic mice commonly display a
hyperactivity phenotype [66, 73, 75, 80] which may pro-
vide analogues to symptoms of agitation, disinhibition and
hyperactivity seen in AD and in some of the FTLD syn-
dromes [81].
In summary, we report two new tau transgenic mouse
models which demonstrate that different molecular path-
ways underlie motor and cognitive tauopathy phenotypes.
The first (L66), based on overexpression of full-length tau
with two pathogenic point mutations, is characterised by
axonopathy and aggressive filamentous tau-aggregation
pathology which is neuroanatomically static and is asso-
ciated with prominent sensorimotor deficits occurring in
the absence of a higher cognitive phenotype. The second
(L1), based on overexpression of the truncated repeat
domain tau fragment which constitutes the bulk of the
PHF-core in AD, shows evidence of neuroanatomical
spread and amplification with age that resembles Braak
staging in AD and is associated with severe cognitive
impairments that progress with age occurring with minimal
sensorimotor impairment. In both models, tau aggregation
can be dissociated from abnormal phosphorylation. The
two models make possible the demonstration of two dis-
tinct but nevertheless convergent pathways of tau
molecular pathogenesis and show that aberrant processing
of APP is not required to explain the differences in the
clinical presentations of AD-like and FTLD syndromes.
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